Wegovy for sleep apnea: why the OSA coverage path runs through Zepbound, not Wegovy

TLDR. Wegovy (semaglutide) is not FDA-approved for obstructive sleep apnea. The OSA indication belongs to Zepbound (tirzepatide), based on the SURMOUNT-OSA trial. Patients with OSA who want a GLP-1 covered under an OSA diagnosis should ask their prescriber about Zepbound, not Wegovy. The Wegovy-for-OSA path runs through cash-pay, off-label, or a different qualifying indication such as established cardiovascular disease.

The confusion is everywhere. A patient gets diagnosed with moderate-to-severe sleep apnea, hears that GLP-1s now treat OSA, asks their telehealth provider for Wegovy, and gets a denial they did not expect. The two products feel interchangeable in the marketing copy. They are not interchangeable in the FDA labeling.

What the SURMOUNT-OSA trial actually tested

SURMOUNT-OSA was a phase 3 trial of tirzepatide (the molecule in Zepbound and Mounjaro), not semaglutide (the molecule in Wegovy and Ozempic). The trial randomized 469 adults with moderate-to-severe obstructive sleep apnea and obesity to tirzepatide 15 mg weekly or placebo for 52 weeks. Results published in NEJM in June 2024 showed:

• Mean reduction in Apnea-Hypopnea Index of 25 to 30 events per hour on tirzepatide, versus roughly 5 on placebo.
• Approximately 43 percent of tirzepatide patients reached disease resolution (AHI less than 5).
• Mean body weight reduction of about 18 to 20 percent.

On the strength of that trial, the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity on December 20, 2024. That approval is product-specific. Wegovy did not run an OSA trial, did not submit an OSA indication, and does not carry an OSA approval.

Why this matters for insurance

Insurance plans authorize medications under specific FDA-approved indications. The PA criteria flow from the label. A Zepbound PA submitted under OSA cites the SURMOUNT-OSA trial, the AHI threshold from the polysomnography report, and the FDA-approved OSA indication. The same documents submitted for Wegovy under an OSA diagnosis do not match a Wegovy-approved indication.

The practical effects:

• Weight-loss-excluded plans. Plans that exclude obesity drugs but cover sleep-disorder treatments will now authorize Zepbound under OSA. They will not authorize Wegovy under OSA.
• Medicare Part D. Wegovy gained Medicare access in 2024 under the cardiovascular indication (SELECT trial). Zepbound gained Medicare access in 2024 under the OSA indication. Two indications, two products, two pathways.
• Step therapy. A plan that requires CPAP trial and failure before covering a drug for OSA will accept that documentation for Zepbound, not Wegovy.

The three honest paths to Wegovy with sleep apnea

If you have OSA and you specifically want Wegovy rather than Zepbound, three real paths exist.

Path 1: a different qualifying indication. If you also have established cardiovascular disease (prior MI, prior stroke, symptomatic PAD), Wegovy is approved under the SELECT cardiovascular indication. Your prescriber codes the prescription under the CV indication, the PA flows from that, and the OSA is a separate ongoing problem managed by your sleep clinician. Roughly 40 percent of patients with moderate-to-severe OSA also meet SELECT-style CV criteria.

Path 2: standard obesity PA. If you have BMI 30 or higher, or BMI 27 with at least one comorbidity, your plan's regular obesity PA process applies. OSA counts as a comorbidity, so a BMI 27 patient with OSA qualifies for a BMI-plus-comorbidity Wegovy PA the same way they would qualify with hypertension or dyslipidemia. The OSA does not move you onto an OSA-specific track for Wegovy because that track does not exist. It just helps satisfy the BMI-27-with-comorbidity threshold.

Path 3: cash-pay. Wegovy is available cash-pay through NovoCare at $499 per month for self-pay patients without coverage, with periodic promotional pricing. Compounded semaglutide remains available through a narrow medical-necessity carve-out at some 503A pharmacies, but the broad compounded path is closed since the FDA shortage resolution in October 2024.

When patients should choose Zepbound instead

If your only qualifying condition is OSA, switch the conversation from Wegovy to Zepbound. The clinical case for tirzepatide in OSA is now stronger than the clinical case for semaglutide in OSA, because the trial that demonstrated the effect was tirzepatide-specific. SURMOUNT-OSA outcomes do not transfer automatically to semaglutide. The dual GLP-1 plus GIP mechanism may matter for the AHI reduction. We will not know until a semaglutide-in-OSA trial reports.

The Zepbound list price is similar to Wegovy. Insurance copays after PA are typically within 30 dollars of each other. The headline-list-price difference is small, and the OSA-coverage difference is large. For an OSA patient, the math favors Zepbound.

What happens during PA review

A typical OSA-flagged Wegovy PA submission produces one of three responses:

• Approved under BMI plus comorbidity. The plan ignores the OSA framing and processes the request as a standard obesity case. Approval at the normal obesity PA timeline (3 to 14 business days).
• Denied with redirect to Zepbound. The plan's reviewer notes that the patient's documented indication (OSA) matches a Zepbound-approved indication, and recommends switching products. This is the most common response in 2026.
• Denied flat. If BMI is under the obesity threshold and the only qualifying condition is OSA, the Wegovy request fails on indication mismatch and the patient must either switch to Zepbound or appeal with additional comorbidity documentation.

The clean fix in scenarios 2 and 3 is to switch the prescription. The slow fix in scenario 3 is the appeal route, which adds 4 to 6 weeks.

The cash-pay reality for Wegovy with OSA

If you are paying cash and have OSA, the price comparison is straightforward. NovoCare self-pay Wegovy lands at roughly $499 per month. LillyDirect self-pay Zepbound vials land at $349 to $499 per month depending on dose. For an OSA patient choosing on price alone, Zepbound vials are usually cheaper, with the added benefit of the matching FDA indication if you later want to switch to insurance billing.

What real-world OSA patients are doing in 2026

Looking at the sleep-medicine clinical and patient-community data, four patterns describe how OSA patients access GLP-1 in practice:

• Sleep-medicine-initiated Zepbound. Patients diagnosed with moderate-to-severe OSA in a sleep clinic, referred for Zepbound under the FDA OSA indication, dispensed through commercial insurance or Medicare Part D. This is the cleanest workflow and the largest patient cohort.
• Primary-care-initiated Zepbound with sleep-study confirmation. Patient brings the polysomnography report to the PCP, PCP writes the Zepbound prescription under OSA. Coverage is similar to path 1.
• Pre-existing Wegovy patient, OSA newly diagnosed. Patient already on Wegovy for obesity, now diagnosed with OSA. Most patients stay on Wegovy because the switch costs 2 to 4 weeks of titration discomfort with little gain. The OSA is a comorbidity that strengthens the obesity-indication PA if it comes up for renewal.
• CPAP failure, looking for an alternative. Patient cannot tolerate CPAP, asks the sleep-medicine clinician about Zepbound. This cohort grew substantially in 2025 after the FDA approval, and sleep-medicine practices have largely absorbed the prescribing.

The dental-appliance and surgery alternatives

Before tirzepatide, the standard non-CPAP OSA options were oral appliances (mandibular advancement devices) and surgery (uvulopalatopharyngoplasty, maxillomandibular advancement, hypoglossal nerve stimulation). For context:

• Oral appliances: 40 to 60 percent reduction in AHI for mild-to-moderate OSA, less effective for severe. Generally well-tolerated. $1,500 to $3,000 cash; usually covered by medical insurance with documentation.
• Hypoglossal nerve stimulation (Inspire): 60 to 70 percent AHI reduction in selected candidates. $30,000 to $40,000 procedure cost. Insurance covers in select indications.
• Maxillomandibular advancement surgery: 80 to 90 percent AHI reduction. High-morbidity surgery, usually a last resort.

Zepbound's 25 to 30 events-per-hour AHI reduction places it between oral appliances and hypoglossal nerve stimulation on raw efficacy, with the added benefit of weight loss and metabolic improvement. For the right patient (obese, moderate-to-severe OSA, CPAP-intolerant or CPAP-augmenting), Zepbound is now a first-line consideration.

Combining Zepbound with CPAP

Many patients on Zepbound for OSA continue CPAP during treatment. As weight comes off and AHI improves, some patients can reduce CPAP pressure or eventually discontinue. The clinical pattern: continue CPAP through the first 6 to 12 months of Zepbound, repeat sleep study at 12 months, adjust or discontinue CPAP based on the new AHI. Sleep medicine should drive the CPAP decision, not the prescribing clinician.

Frequently asked questions

Does Wegovy work for sleep apnea even if it is not FDA-approved for OSA?

Probably yes, mechanistically. Semaglutide produces 10 to 15 percent weight loss, and weight loss reduces AHI in OSA patients regardless of the mechanism that drives the weight loss. The clinical benefit on OSA outcomes is plausible. The trial proving it has not been run on semaglutide. So you cannot use that off-label assumption to get insurance coverage under an OSA indication.

Will my insurance cover Wegovy if I have CPAP intolerance?

If CPAP intolerance is documented and you have BMI 27 with a comorbidity, the standard obesity PA process applies. CPAP intolerance does not unlock a special OSA pathway for Wegovy, because Wegovy does not have an OSA pathway. It does, however, support the broader medical-necessity argument and can strengthen an appeal.

Can I switch from Wegovy to Zepbound for the OSA indication?

Yes. The switch is clinically routine. Most prescribers will start Zepbound at 2.5 mg weekly regardless of your prior Wegovy dose, then titrate. Coverage under the OSA indication usually requires the polysomnography report (AHI documentation) and your obesity diagnosis. Plan to spend 1 to 4 weeks on PA processing during the switch.

What if I cannot tolerate tirzepatide and Wegovy is my only option?

Document the tirzepatide trial and discontinuation reason. Submit the Wegovy PA under BMI plus comorbidity, with OSA listed as the qualifying comorbidity. The CPAP failure record strengthens the medical-necessity argument. Appeals at this stage cite the obesity indication, not the OSA indication. Roughly 60 percent of these appeals succeed inside 6 weeks per published payer data.

Is the dual-product situation likely to change?

Novo Nordisk has not publicly announced an OSA trial for semaglutide. As long as that is the case, Wegovy will remain a non-OSA-indicated product. A future SURMOUNT-OSA equivalent for semaglutide could change the labeling. There is no announced trial timeline as of mid-2026.

For the Zepbound-specific OSA pathway, see our Zepbound OSA indication article. For the cardiovascular pathway that can cover Wegovy when OSA cannot, see the SELECT MACE deep-dive and Wegovy for cardiovascular secondary prevention. To compare the two drugs head to head on price and efficacy, see tirzepatide versus semaglutide direct comparison. For the OSA condition page with PA letter templates, see our OSA condition guide.

Citations

• Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. NEJM 2024;391:1193-1205. nejm.org/doi/full/10.1056/NEJMoa2404881
• FDA Press Release, December 20 2024: FDA approves first medication for obstructive sleep apnea. fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
• Wegovy prescribing information, Novo Nordisk, current label. accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• Zepbound prescribing information, Eli Lilly, current label. accessdata.fda.gov/drugsatfda_docs/label/2024/217806s002lbl.pdf
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221-2232. nejm.org/doi/full/10.1056/NEJMoa2307563